Philippe Roingeard obtained a Pharm D (1984) and a PhD in Cell Biology and Virology (1988) at the University of Tours, Loire Valley, France, prior to taking on a position of Research Associate in the Department of Cancer Biology at the Harvard School of Public Health (1988-1991), Boston, USA. He is currently professor of Cell Biology at the University of Tours and hospital practitioner at the University Hospital in Tours. He is a member of the research team INSERM U 1259 "Morphogenesis and antigenicity of HIV and hepatitis viruses" in Tours, which he directed between 2006 and 2023. Philippe Roingeard was vice-President of the Scientific Commission "Basic research on viral hepatitis" of the French Agency for Research on AIDS, Viral Hepatitis and Emerging Infectious Diseases (ANRS-MIE). He is the author or co-author of 181 international publications indexed in Medline. His main research interests are the morphogenesis and pathogenesis of different viruses, especially HBV and HCV, and he is currently focusing its research on the development of a bivalent HBV- HCV vaccine. He has received several awards for his research on viruses: French National Academy of Medicine (2014), Fondation de France (2015), French National Academy of Pharmacy (2018).